Reading SRRK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SRRK free→Reading SRRK? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track SRRK free→QuarterlyIQ Insights · SRRK
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 7, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities E…
Other Events. On March 31, 2026, the Company announced that it resubmitted its BLA to the FDA for apitegromab for the treatment of children and adults with SMA. The Company anticipates FDA acceptance within 30 days and a review period of up to six months from the date of resubmission, with a Prescription Drug User Fee Act (“PDUFA”) action date expected in late September 2026. Cautionary Notes on Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” w…
Results of Operations and Financial Condition. On March 3, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the year ended December 31, 2025 and to provide a business update. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K.
of the Current Report on Form 8-K filed on March 3, 2026 (the “Original Form 8-K”) solely to correct an error in the Earnings Release furnished as Exhibit 99.1 thereto (the “Exhibit”). As previously furnished, the Exhibit reflected a scrivener’s error relating to the net loss per common share for the quarter ended December 31, 2025 and the weighted average common shares outstanding, basic and diluted, for the quarter ended December 31, 2025, which has been corrected on Exhibit 99.1 to this Am…
Other Events. The Company will be conducting meetings with participants attending the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”) during the week of January 12, 2026. A copy of the slides to be presented by the Company at the Conference is filed as Exhibit 99.2 to this Current Report on Form 8-K. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2. Forward-Looking Statements This Current Report on Form 8-…
Results of Operations and Financial Condition. On January 12, 2026, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its preliminary cash balance as of December 31, 2025, a business update and further details on its 2026 strategic priorities. Although it has not finalized its full financial results for the fourth quarter and fiscal year ended December 31, 2025, the Company announced on January 12, 2026, that it estimates it had approximately $365 million…
Results of Operations and Financial Condition. On November 14, 2025, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the fiscal quarter ended September 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of t…
Other Events. As previously disclosed, Scholar Rock Holding Corporation (the “Company”) entered into an Open Market Sale Agreement SM , dated November 14, 2022 with Jefferies LLC (“Jefferies”) relating to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (“Common Stock”) through Jefferies as sales agent (the “ATM Program”). On November 14, 2025, the Company filed a pros…
Other Events. On September 23, 2025, the Company announced that the FDA has issued a CRL regarding the BLA for apitegromab for the treatment of SMA.
Regulation FD Disclosure. On September 23, 2025, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (“FDA”) has issued a Complete Response Letter (“CRL”) regarding the Biologics License Application (“BLA”) for apitegromab for the treatment of spinal muscular atrophy (“SMA”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The informati…
Results of Operations and Financial Condition. On August 6, 2025, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the fiscal quarter ended June 30, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Secur…
Changes in Registrant’s Certifying Accountant. (b) Engagement of New Independent Registered Public Accounting Firm On June 3, 2025, the Audit Committee (the “Audit Committee”) of the Board of Directors of Scholar Rock Holding Corporation (the “Company”) appointed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The Audit Committee conducted a competitive process in which multiple firms were invited…
Results of Operations and Financial Condition. On May 14, 2025, Scholar Rock Holding Corporation (the “Company”) issued a press release announcing its financial and operating results for the quarter ended March 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information in this Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Ex…
Changes in Registrant’s Certifying Accountant. On May 6, 2025, Scholar Rock Holding Corporation, a Delaware corporation (the “Company”), received notice from Ernst & Young LLP (“EY”), the Company’s independent registered public accounting firm, of its decision to decline to stand for re-election as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. EY will cease providing services following the filing of the Form 10-Q for the quarter endi…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Management Transition On April 26, 2025, the Board of Directors (the “Board”) of Scholar Rock Holding Corporation and Scholar Rock, Inc. (collectively, the “Company”) appointed Mr. David Hallal as Chief Executive Officer of the Company effective as of April 27, 2025 (the “Transition Date”) following Dr. Jay T. Backstrom’s transition from his role a…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.